GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2009

Eurogentec to Acquire Proteomics Company AnaSpec

  • Eurogentec negotiated a final agreement for the acquisition of Fremont, CA-based AnaSpec. The company is a specialist provider of integrated proteomics solutions for life science research and diagnostics.

    Eurogentec claims combining AnaSpec’s expertise with its own capabilities will allow it to provide innovative solutions in the fields of genomics and proteomics for basic research in the biotech and pharma sectors as well as applied solutions for the diagnostics industry. For example, comments Jean-Pierre Delward, Eurogentec CEO, “The HiLyte Fluor™ dyes and QXL™ quenchers that are part of AnaSpec’s high-performance detection assays will be integrated into Eurogentec’s comprehensive portfolio of oligonucleotides. This will establish a license-friendly alternative to most dye-labeled oligonucleotides from competitors for commercial and diagnostic applications.”

    Eurogentec also points out that the AnaSpec acquisition will significantly strengthen its presence in the U.S. The company plans to market and support AnaSpec’s products directly in the EU.

    AnaSpec’s current product and service portfolio includes GMP and GLP custom peptide synthesis labeled primary antibodies, labeled secondary antibodies, and labeled streptavidin. The company also claims to offer one of the largest collections of catalog and dye-labeled peptides in the fields of Alzheimer’s disease, multiple sclerosis, and enzyme inhibitor screening. AnaSpec moved into its new, 44,010 square foot headquarters in Fremont in April.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?